Open AccessCetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Author(s) -
Janja Ocvirk,
Thomas Brodowicz,
Fritz Wrba,
Tudor-Eliade Ciuleanu,
G. Kurteva,
S. Beslija,
I Koza,
Zsuzsanna Pápai,
Diethelm Messinger,
Uğur Yılmaz,
Zsolt Faluhelyi,
Şuayib Yalçın,
Demetris Papamichael,
M. Wenczl,
Zrinka Mršić-Krmpotić,
Einat ShachamShmueli,
Damir Vrbanec,
Regina Esser,
Werner Scheithauer,
Christoph Zielinski
Publication year - 2010
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v16.i25.3133
Subject(s) - cetuximab , folfiri , kras , folinic acid , medicine , oxaliplatin , irinotecan , colorectal cancer , folfox , hazard ratio , oncology , progression free survival , gastroenterology , chemotherapy , cancer , confidence interval
To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC).